TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7208542
Drug: Iron poly
Normalized name: iron polymaltose
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron poly (sorbitol‐gluconic acid) complex (IPSG) 500 mg elemental iron per week for 8 weeks
Study: 6831362
Drug: Levamisole (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (45 mg/m2, orally, twice daily for three consecutive days each week)
Study: 6831362
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (daunorubicin and cytosine arabinoside for induction and consolidation, methotrexate with citrovorum factor reversal, thioguanine and cytosine arabinoside for late intensification)
Study: 26196201
Drug: 10,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 IU of oral vitamin D3/10 kg body weight per week for 6 weeks
Study: 26196201
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU of oral vitamin D3/10 kg body weight per week for 6 weeks
Study: 25012515
Drug: CX157 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CX157 treatment
Study: 22273828
Drug: Ramosetron 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 6 μg/kg
Study: 22273828
Drug: Ramosetron 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 6 μg/kg and midazolam 0.1 mg/kg
Study: 17919233
Drug: High-dose PegIFN-alpha-2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose PegIFN-alpha-2b (3.0 microg/kg once weekly for 12 weeks, then 2.0 microg/kg once weekly for 12 weeks, then 1.5 microg/kg once weekly for 48 weeks)
Study: 17919233
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of PegIFN-alpha-2b (1.5 microg/kg once weekly for 48 weeks)
Study: 15619603
Drug: Ketoprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (100 mg) before induction of anaesthesia (group K1)
Study: 15619603
Drug: Propacetamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol (2 g) before induction of anaesthesia (group P1)
Study: 15619603
Drug: Saline before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline before surgery and ketoprofen (100 mg) after surgery (group K2)
Study: 15619603
Drug: Saline before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline before surgery and propacetamol (2 g) after surgery (group P2)
Study: 10088167
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray (large-particle aerosol)
Study: 465281
Drug: Aspirin (1280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1280 mg each)
Study: 465281
Drug: Dimenhydrinate (Dramamine)
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimenhydrinate (Dramamine) (100 mg each)
Study: 2178493
Drug: Intramuscular clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular clonidine (2 micrograms/kg)
Study: 6775303
Drug: pentaerythritol tetranitrate
Normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pentaerythritol tetranitrate (PETN) 80 mg 8-hourly
Study: 6775303
Drug: dipyramidole (DPM)
Normalized name: DPM-1001
DrugBank: DPM-1001 (DB18390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dipyramidole (DPM) 75 mg
Study: 26553159
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (24 weeks)
Study: 26553159
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (24 weeks)
Study: 15246912
Drug: SLV306 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV306 (200 mg)
Study: 15246912
Drug: SLV306 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV306 (400 mg)
Study: 15246912
Drug: SLV306 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV306 (800 mg)
Study: 15246912
Drug: SLV306 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV306 (all doses)
Study: 9509213
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (Group B)
Study: 3289804
Drug: Immunosuppressants (corticosteroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressants (corticosteroids, cyclophosphamide, azathioprine)
Study: 3289804
Drug: Immunosuppressants (corticosteroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressants (corticosteroids, cyclophosphamide, azathioprine) + Plasma exchange therapy
Study: 25633123
Drug: Accelerated Ponseti
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Ponseti technique (casting twice a week)
Study: 20874740
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) 0.25 mg/kg twice daily at postnatal day 1 and 2
Study: 18929194
Drug: Anterior transposition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior transposition (subcutaneous or submuscular)
Study: 15011734
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patches (17.5 mg/day)
Study: 8339079
Drug: Topical PROCUREN
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical PROCUREN (autologous platelet-derived wound healing factors)
Study: 26557261
Drug: Fluticasone (FP)
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (FP) 500 µg bid, five doses total
Study: 23497111
Drug: MTX responders
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX responders (triple therapy)
Study: 18343702
Drug: 24-hour therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour therapy with artesunate/sulfamethoxypyrazine/pyrimethamine (As/SMP)
Study: 18343702
Drug: 3-day therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day therapy with artesunate/sulfamethoxypyrazine/pyrimethamine (As/SMP)
Study: 16417952
Drug: MCV-4 (meningococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCV-4 (meningococcal diphtheria toxoid conjugate vaccine)
Study: 16417952
Drug: Hib vaccine
Normalized name: ActHIB vaccine 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib vaccine (control group)
Study: 8193732
Drug: Felodipine 5-20
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5-20 mg orally once daily for 8 weeks
Study: 8193732
Drug: Enalapril 5-20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5-20 mg orally once daily for 8 weeks
Study: 31965734
Drug: Trauma-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused therapy (TFT)
Study: 31350967
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (50,000 IU weekly for 2 months)
Study: 26179985
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group received a single shockwave treatment with 1000 impulses at 0.19-0.23 mJ/mm²
Study: 25163030
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 supplement (daily)
Study: 19816204
Drug: Low propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low propofol (4 mg/kg/h)
Study: 19816204
Drug: High propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High propofol (6 mg/kg/h)
Study: 16187808
Drug: Interactive Voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Voice Response (IVR) system for daily reports of cigarette use.
Study: 16187808
Drug: Timeline Follow-Back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Timeline Follow-Back (TLFB) method for daily reports of cigarette use.
Study: 12042274
Drug: Day 5
Normalized name: One-A-Day 50+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 5 inhibin B >400 pg/ml
Study: 12042274
Drug: Day 5
Normalized name: One-A-Day 50+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 5 inhibin B <400 pg/ml
Study: 6350616
Drug: Ceftazidime 250
Normalized name: ceftazidime 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 250 mg administered intramuscularly every 12 hours
Study: 6350616
Drug: Ceftazidime 500
Normalized name: ceftazidime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 500 mg administered intramuscularly every 12 hours
Study: 6350616
Drug: Ceftazidime 1000
Normalized name: ceftazidime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 1000 mg administered intramuscularly every 12 hours
Study: 20004036
Drug: Taking anti-hypertensive
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking anti-hypertensive medication
Study: 16316359
Drug: Oral paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral paricalcitol (mean dose 9.5 microg/week)
Study: 9689834
Drug: Steroids (previous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (previous treatment)
Study: 8075780
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) carbimazole 60 mg plus thyroxine 100-150 micrograms daily
Study: 8075780
Drug: Titration-dose (TD)
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration-dose (TD) carbimazole
Study: 8075780
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) and Titration-dose (TD) regimens
Study: 31544547
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of transcatheter arterial chemoembolization (TACE) treatment
Study: 29221779
Drug: 9-g sodium
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-g sodium oxybate (SXB)/nightly
Study: 29221779
Drug: 200-600 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-600 mg/d modafinil
Study: 21316259
Drug: Paravertebral block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral block (PVB) group (n=20) - 15 ml of ropivacaine 0.2% every 6h combined with endovenous metamizol (1g)
Study: 21316259
Drug: Alternate NSAIDs
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate NSAIDs group (AN) (n=20) - Paracetamol (1g) combined with metamizol (1g) every 6h
Study: 20055118
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg b.i.d.
Study: 20055118
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg q.d.
Study: 11752357
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg every morning) before ibuprofen (400 mg every morning)
Study: 11752357
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg every morning) before acetaminophen (1000 mg every morning)
Study: 11752357
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg every morning) before rofecoxib (25 mg every morning)
Study: 11752357
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin before ibuprofen (400 mg three times a day)
Study: 11752357
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin before delayed-release diclofenac (75 mg twice daily)
Study: 11752357
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg every morning) after ibuprofen (400 mg every morning)
Study: 11752357
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily doses of ibuprofen before aspirin
Study: 9407270
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) for OCD, consisting of 12 weekly sessions.
Study: 3814463
Drug: Sulindac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (200 mg)
Study: 3814463
Drug: Piretanide (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (6 mg)
Study: 3814463
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg) with Hydrochlorothiazide (100 mg)
Study: 3814463
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg) with Piretanide (6 mg)
Study: 3814463
Drug: Sulindac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (200 mg) with Hydrochlorothiazide (100 mg)
Study: 3814463
Drug: Sulindac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (200 mg) with Piretanide (6 mg)
Study: 29538682
Drug: Single vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vaccination with quadrivalent inactivated influenza vaccine (QIV)
Study: 29538682
Drug: Booster vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccination with quadrivalent inactivated influenza vaccine (QIV)
Study: 28018112
Drug: Repeated capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeated capsaicin infusion
Study: 28018112
Drug: Acute capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute capsaicin infusion
Study: 24659021
Drug: Lenalidomide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (10 mg × 7 days) alone
Study: 24659021
Drug: Lenalidomide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (10 mg × 7 days) with digoxin (0.5 mg on Day 5)
Study: 24659021
Drug: Lenalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (25 mg single dose) alone
Study: 24659021
Drug: Quinidine (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (300-600 mg twice-daily × 5 days) plus lenalidomide (on Day 4)
Study: 24659021
Drug: Temsirolimus (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (25 mg single dose) alone
Study: 24659021
Drug: Lenalidomide plus
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide plus temsirolimus (25 mg single dose)
Study: 22572767
Drug: Donepezil 23
Normalized name: donepezil 23 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 23 mg/day with memantine
Study: 22572767
Drug: Donepezil 23
Normalized name: donepezil 23 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 23 mg/day without memantine
Study: 22572767
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg/day with memantine
Study: 22572767
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg/day without memantine
Study: 18425522
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (IVTA) injection
Study: 25837212
Drug: Lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle modification (LSM) with 80g pistachios daily for 3 months
Study: 21724564
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (loading dose 1 g over 10 minutes, then infusion of 1 g over 8 hours)
Study: 15848673
Drug: Complete steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete steroid avoidance (standard therapy without steroid induction/maintenance)
Study: 15848673
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (tacrolimus, mycophenolate mofetil, steroid induction/maintenance)
Study: 15848673
Drug: Complete steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete steroid avoidance
Study: 11999667
Drug: BH4 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BH4 (1 mg/min)
Study: 8672316
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 1 ml kg‐1 with clonidine 2 micrograms kg‐1
Study: 8672316
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 1 ml kg‐1 with adrenaline 5 micrograms ml‐1 (1/200,000)
Study: 23973
Drug: Oxypertine 30
Normalized name: oxypertine
DrugBank: Oxypertine (DB13403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxypertine 30 mg daily
Study: 23973
Drug: Oxypertine 60
Normalized name: oxypertine
DrugBank: Oxypertine (DB13403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxypertine 60 mg daily
Study: 25879932
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) delivered by psychologists with usual care
Study: 20569223
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium valproate, loading dose of 900-1200 mg
Study: 14963702
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 0.3 mg/kg per day for 3 days + 2 g/kg IVIG over 4 to 5 days
Study: 14963702
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: 2 g/kg IVIG over 4 to 5 days + higher dose acetylsalicylic acid
Study: 11588947
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg transdermal estradiol twice weekly
Study: 11588947
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg oral conjugated estrogen daily with 2.5 mg oral medroxyprogesterone acetate daily
Study: 11588947
Drug: Transdermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapy
Study: 7798545
Drug: Azelastine 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 0.1% (1 spray [0.12 mg] per nostril every 12 hours, 2 sprays per nostril every 12 hours, or 2 sprays per nostril once daily)
Study: 7798545
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate (12 mg twice daily)
Study: 2647645
Drug: reserpine, prazosin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: reserpine, prazosin, indapamide, atenolol (separately or in combination)
Study: 825133
Drug: Methaqualone hydrochloride
Normalized name: Methaqualone hydrochloride
DrugBank: Methaqualone (DB04833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methaqualone hydrochloride (400 mg)
Study: 825133
Drug: Methaqualone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methaqualone (20 and 30 mg/kg body weight) in monkeys
Study: 31403168
Drug: Cognitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive and behavioral therapy for insomnia (CBT-i)
Study: 29095305
Drug: Direct intramuscular
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct intramuscular injection of MSCs (1*10 cells in 1 mL of 0.9% saline)
Study: 29095305
Drug: Placebo-controlled group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-controlled group (1 mL of 0.9% saline)
Study: 26465872
Drug: Statins +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins + Amlodipine + Renin-Angiotensin-Aldosterone System Inhibitors (Benazepril or Losartan)
Study: 26465872
Drug: Amlodipine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine + Renin-Angiotensin-Aldosterone System Inhibitors (Benazepril or Losartan) without Statins
Study: 19190515
Drug: Investigational arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational arm (first-line chemotherapy)
Study: 19190515
Drug: Reference arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference arm (first-line chemotherapy)
Study: 12677732
Drug: Taste strips
Normalized name: 60 Second Taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taste strips impregnated with different taste solutions (four concentrations each for sweet, sour, salty, and bitter)
Study: 9268956
Drug: 20 mg.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg.kg-1 dose of powdered aspirin
Study: 9268956
Drug: Placebo (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (water and Kool-Aid mixture without aspirin)
Study: 27898699
Drug: Caregivers' physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregivers' physical access to SMC medication
Study: 20128827
Drug: Implant stability
Normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant stability quotient (ISQ) measured in buccolingual direction
Study: 20128827
Drug: Implant stability
Normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant stability quotient (ISQ) measured in mesiodistal direction
Study: 11665796
Drug: 800,000 units
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800,000 units of intravenous monteplase followed by rescue PTCA
Study: 9628067
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) administered subcutaneously at a dosage of 9,000,000 U.I. b.i.d. for three days before surgery
Study: 8166943
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg daily from mean gestational age of 17.7 weeks
Study: 23747824
Drug: G-Bond (GB;
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond (GB; GC)
Study: 19768649
Drug: Fosfomycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (3 g single dose)
Study: 19768649
Drug: Amoxicillin-clavulanate (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (7-day regimen)